ERBB2 and breast carcinoma: Thus, the co-expression of ASCT2, SLC7A5 and SLC3A2 may serve as potential biomarkers for identifying ER+ highly proliferative subclass and HER2+ subclass of breast cancer patients at higher risk of poor response to endocrine therapy.